side effects tirzepatide vs semaglutide Weighing up the Risks: GI of tirzepatide and semaglutide therapeutic modality

Zepbound: On November 8, 2023 the FDA announced the approval of tirzepatide injections for: chronic weight management in adults with obesity (body mass index of 30 kilograms per square meter (kg/ m2) or greater) or overweight (body mass index of 27 kg/m2 or greater) with at least one weight-related condition (such as high blood pressure, type 2 diabetes or high cholesterol) for use, in addition to a reduced calorie diet and increased physical activity. Tirzepatide for Diabetes, Weight Loss and Hypertension

Recent studies have shown that circulating DPP-4 plays a role in obesity and cardiovascular diseases, and may represent an important molecular link between obesity, diabetes, and cardiovascular disease (Rhrborn et al., 2015)

This underscores the critical need for integrated investigations examining microbiome-atherosclerosis interactions specifically in SLE contexts

Khng s dng cho tr em, ph n mang thai v m ang cho con b,